Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- PFIZER INC - Research Update.
- New Data On Pfizer's Aromasin and Ellence to Be Presented at San Antonio Breast Cancer Symposium Pfizer Begins...
- Research articles 2006-12-15
- Solucient Study: Radiation Therapy Used for Less than Half of Senior Patients Following Key Breast Cancer Procedure
- EVANSTON, Ill., Oct. 24 /U.S. Newswire/ -- Findings released by Solucient confirm a trend verified by medical researchers in recent years -- senior women who undergo breast-conserving surgery, or "lumpectomy", to treat breast cancer often do notEVANSTON, Ill., Oct. 24 /U.S. Newswire/ -- Findings released by Solucient confirm a trend...
- Research articles 2003-10-24
- Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor Therapy
- A Study Evaluating Twice Yearly Dosing with Denosumab Met All Primary and Secondary Endpoints
- Research articles 2007-12-15
- Genetech's Monoclonal Antibody Receives Preliminary FDA Approval.
- GENETECH INC. has moved a step closer to receiving Food and Drug Administration approval for Herceptin trastuzumab, a humanized monoclonal antibody, as a single agent in second- and third-line therapy and in combination with paclitaxel in first-lin GENETECH INC. has moved a step closer to receiving...
- Research articles 1998-09-07
- Breast Cancer Patients Switched to Pfizer's Aromasin Were More Likely to Remain Cancer Free, Study Shows; Results From Pfizer-Sponsored Study Challenge Standard Tamoxifen Therapy.
- Byline: Edelman Public Relations Byline: Edelman Public Relations
- Research articles 2004-03-10
- Aetna limits breast cancer marrow therapy.(Brief Article)
- BLUE BELL, Pa.-Aetna U.S. Healthcare said last week it will limit coverage of a particular treatment for advanced breast cancer because researchers have failed to establish its effectiveness. Meanwhile, other health maintenance organizations say th BLUE BELL, Pa.-Aetna U.S. Healthcare said last week it...
- Research articles 2000-02-21
- First-Line Therapy With Gemcitabine and Paclitaxel in Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
- This phase II study evaluated the efficacy and safety of gemcitabine G plus paclitaxel T as first-line therapy in recurrent or metastatic breast cancer. Patients with locally recurrent or metastatic breast cancer and no prior chemotherapy for metastatic disease received G 1200 mg/m2 on days 1 and 8, and T...
- White papers 2005-11-29
Additional Resources
- Lilly Oncology Prepares for Strong Showing at ASCO 2006; Targets Breast Cancer and Other Tumors with 79 Studies.(Company overview)
- INDIANAPOLIS, May 23 /PRNewswire/ -- - 11 breast cancer studies; 29 thoracic cancer studies; and 8 studies with developing targeted agent Lilly Oncology, a global leader in thoracic cancer treatment, will be presenting important data on its emerging research in breast...
- Research articles 2006-05-23
- Immunicon Corporation to Conduct Circulating Tumor Cell Testing for Breast Cancer Clinical Trial Conducted by the Southwest Oncology Group
- HUNTINGDON VALLEY, Pa. -- Immunicon Corporation (NASDAQ-GM:IMMC) announced today that a major clinical trial conducted by the Southwest Oncology Group SWOG has opened to enrollment. The trial is a randomized Phase III trial designed to determine whether changing cancer therapy when circulating tumor cells CTCs are elevated at the first...
- Research articles 2006-11-28
- Use of Hyperthermia Therapy in Treating Primary and Recurrent Breast Cancer Highlights Breast Cancer Congress
- BSD Medical Corp. (AMEX: BSM) today announced that breakthrough uses of hyperthermia therapy in treating both recurrent and primary breast cancer drew much attention and was a major highlight at the twelfth annual Puerto Rico Breast Cancer Conference held in conjunction with the American Cancer Society October 27-29 in San...
- Research articles 2006-11-08
- WIN Against Breast Cancer With SnowPack Pink Ribbon Kit.
- Byline: Women's Information Network Against Breast Cancer SANTA FE, N.M., June 3 AScribe Newswire -- SnowPack Cold Therapy has joined forces with the national nonprofit Women's Information Network Against Breast Cancer WIN ABC organization to introduce the SnowPack Pink Ribbon Kit. Designed for ice...
- Research articles 2005-06-03
- Clarient: New Breast-Cancer Test
- Douglas Cress submits: For women who survive breast cancer, the triumph of beating the odds is often tempered by a fear of the cancer returning. A study published last year in the Journal of the National Cancer Institute looked at 3,000 breast cancer patients, and found that the group averaged...
- External links 2009-05-05
- Cleveland Clinic Installs OmniCorder's BioScanIR System to Monitor Response to Neoadjuvant Breast Cancer Therapy
- EAST SETAUKET, N.Y -- OmniCorder Technologies, Inc. (OTCBB Symbol: OMCT) today announced the delivery of a new cancer therapy monitoring configuration of its BioScanIRR System to The Cleveland Clinic. The system will be used to detect the effects of cancer treatments in patients undergoing neoadjuvant breast cancer therapy as part...
- Research articles 2004-11-01
- First Mobetron in Germany, 24th Worldwide: Renowned CDT Breast Cancer Center in Cologne Selects IntraOp Medical's Mobetron Device for Advanced Intraoperative Electron Radiation Therapy
- SUNNYVALE, Calif. -- IntraOp Medical Corporation (OTCBB: IOPM), a provider of innovative technology solutions for the treatment and eradication of cancer, announced today that the CDT Strahleninstitut Koln, a renowned breast cancer center in Cologne, Germany has selected Mobetron for advanced breast cancer treatment. Mobetron directly delivers intraoperative electron radiation...
- Research articles 2007-11-08
- Nuvera Biosciences Presents Advances in Breast Cancer Genomic Assays at ASCO Annual Meeting
- Direct comparison of predicted therapy outcomes with cancer prognosis identifies patients at both low and high risk of recurrence who would benefit from therapy WOBURN, Mass. -- Nuvera Biosciences, a molecular diagnostics company, reports significant advances in breast cancer genomic assays on endocrine therapy and chemotherapy outcomes. The research...
- Research articles 2008-05-29
- New Gene Active in 80 Percent of Breast Cancer Patients, GWU- Patricia Berg Team Reports; Target for Early Detection and Therapy
- WASHINGTON, April 18 /U.S. Newswire/ -- The following was released today by George Washington University Medical Center: -- Gene Active in 80 Pct. of Breast Cancer Patients, GWU-Patricia Berg Team Reports; Target for Early Detection and Therapy --While Overall Impact, More African American Breast Cancer Patients Express Gene and Could...
- Research articles 2003-04-22
- Does Energy Balancing Therapy Provide Relief for Breast Cancer Patients?; Women's Health @ Stanford Offers Free Therapy and Studies Its Effects
- STANFORD, Calif. -- Catherine Palter recalled being skeptical as she began her first session of a complementary therapy, known as Healing Touch, to try to ease the nausea, fatigue and feelings of fear and worry that accompanied her breast cancer treatment. "I didn't expect to feel anything," said Palter, a...
- Research articles 2006-05-16
- The Vital First Years in Breast Cancer Care.
- LONDON, May 11 /PRNewswire/ -- - How Can Women Live Cancer Free for Longer? - 80% of postmenopausal women with breast cancer can benefit from adjuvant hormonal therapy, such as 'Arimidex' anastrozole - Women with early breast cancer have a...
- Research articles 2005-05-11
- Celsion Presents Preliminary Breast Cancer Treatment Results at 56th Annual Cancer Symposium, Society of Surgical Oncology
- Business Editors/Health/Medical Writers COLUMBIA, Md.--BUSINESS WIRE--March 10, 2003 96% of Lumpectomy Patients Treated with Thermotherapy in Study Require No Further Surgery CELSION CORPORATION (AMEX:CLN) has announced that Dr. Hernan I. Vargas, co- principal investigator for Celsion's Pivotal Breast Cancer Clinical Trials and Chief of Surgical Oncology...
- Research articles 2003-03-10
- Chiron and Ciba announce FDA market clearance of Aredia® for treatment of patients with Osteolytic Bone Metastases of breast cancer; First Therapeutic For Osteolytic Bone Metastases Associated with Breast Cancer
- EMERYVILLE, Calif. and SUMMIT, N.J.--HealthWire--August 12, 1996-- Chiron Therapeutics, a business unit of Chiron Corporation (Nasdaq: CHIR), and Ciba Pharmaceuticals, a division of Ciba-Geigy Corporation jointly announced today that the United States Food and Drug Administration FDA has cleared ArediaR pamidronate disodium for injection for marketing for the treatment of...
- Research articles 1996-08-12
- << Previous
- page 1 of 1
- Next >>
Presented by American Express